Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma

Andrew B. Katims, Peter A. Reisz, Lucas Nogueira, Hong Truong, Andrew T. Lenis, Eugene J. Pietzak, Kwanghee Kim, Jonathan A. Coleman

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


This review describes the current landscape of targeted therapies in urothelial carcinoma. The standard of care for advanced urothelial carcinoma patients remains platinum-based combination chemotherapy followed by immunotherapy. However, median overall survival for these patients is still <1 year and there is an urgent need for alternative therapies. The advent of next-generation sequencing has allowed widespread comprehensive molecular characterization of urothelial tumors and, subsequently, the development of therapies targeting specific molecular pathways implicated in carcinogenesis such as FGFR inhibition, Nectin-4, Trop-2, and HER2 targeting. As these therapies are demonstrated to be effective in the second-line setting, they will be advanced in the treatment paradigm to localized and even non-muscle invasive disease.

Original languageEnglish (US)
Article number5431
Issue number21
StatePublished - Nov 2022

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma'. Together they form a unique fingerprint.

Cite this